Heuer Dale K
In this database
7
2017 โ 2025
DB Citations
157
across indexed articles
h-index
โ
Not available
Total Citations
โ
Not available
7 articles in Glaucoma Journal Club
The Primary Tube Versus Trabeculectomy Study: Methodology of a Multicenter Randomized Clinical Trial Comparing Tube Shunt Surgery and Trabeculectomy with Mitomycin C.
Practice patterns vary in the surgical management of glaucoma, and opinions differ among surgeons regarding the preferred primary operation for glaucoma.
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up.
In this study, only one-fourth of participants in the Ocular Hypertension Treatment Study developed visual field loss in either eye over long-term follow-up.
Comparing Treatment Outcomes from the Tube Versus Trabeculectomy and Primary Tube Versus Trabeculectomy Studies.
Differences in patient characteristics between the PTVT and TVT Studies, including the level of preoperative intraocular pressure, contributed to the differences in surgical failure rates in each trial.
Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study.
Endpoint Committee adjudication of endpoints improved POAG incidence estimates, increased statistical power, and increased calculated treatment effect by 23%.
Visual Field Progression in the Ocular Hypertension Treatment Study.
Some participants in OHTS had rapid rates of VF loss in one or both eyes despite being followed in a clinical study.
Quality of Life and Primary Open-Angle Glaucoma in the Ocular Hypertension Treatment Study.
In this cross-sectional study, among the surviving participants of OHTS who completed the 20-year follow-up examination, those participants who developed preperimetric POAG but no glaucomatous VF loss did not report lower VFQoL compared with participants who did not develop POAG.
Something Old (Trabeculectomy), Something New (Ab Interno Gelatin Microstent): Finally, a Marriage of Innovation and Outcome Data (without Concurrent Cataract Surgery)!